ESMO AI at a glance

Get ready for ESMO AI and Digital Oncology 2025 with LucidQuest’s concise preview—spotlighting must-see sessions and emerging themes in AI-driven oncology.

📅 Build your schedule around the topics that interest you. 📥 Download the ESMO -AI 2025_Preview_by_LucidQuest.

Dive deeper

Key Topics From Notable Presentations on Artificial Intelligence & Machine Learning

AI for Treatment Response, Immunotherapy & Precision Oncology

• AI biomarkers and digital pathology set to personalize therapy selection and predict response across major tumor types.

Personalized Biomarkers & Predictive Models

• Multi-omic profiling in NSCLC, TNBC, melanoma identifies pTLS and immune signatures, enabling immunotherapy and ADC selection.

AI in Prognosis & Survival Prediction

• SVM and XGBoost forecast overall survival and long-term outcomes in mNSCLC, CRC, aHCC, supporting risk stratification and tailored follow-up.

Innovative AI for Diagnosis & Scheduling

• Early NSCLC detection and circadian ICI timing tools aim to optimize workflows and improve therapeutic efficacy.

AI-Driven Oncology Decision Support

• ClioAssist and Konsuld® set to automate workflows, provide real-time decision support, and enable global peer consultations.

Digital Health, Patient Monitoring & ePROs

• AI tools, wearables, and integrated ePRO platforms enable real-time symptom tracking, streamline workflows, and improve quality of life.

Radiomics & Imaging AI

• Radiomics predicts EGFR mutations, HER2 status, and glioma subgroups, offering noninvasive biomarkers to guide precision treatment.

Breast Recurrence Risk Prediction

• Deep learning on histopathology + clinical data achieved AUC 0.898, reclassifying high-risk patients and reducing unnecessary chemotherapy.

MSI Detection in Gastric Cancer

• Equivariant Neural Field reached AUC 70.0 on biopsies, outperforming baselines while reducing computational complexity.

Trial Matching for Lung Cancer

• LungTrial-LLMX achieved 83% patient–trial matching accuracy using a privacy-preserving dual-LLM design with transparent reasoning.

LLMs for MDT Decisions

• Initial concordance 67.2% for MDT use; ChatGPT-5 reached 75.7% for breast adjuvant recommendations, expanding discussion breadth and options.

📅 Build your schedule around the topics that interest you.

📥 Download the ESMO -AI 2025_Preview_by_LucidQuest

Contact us for end-to-end conference coverage.